Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

Complete title: Phase 1 study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma

Research Study Number 9736
Principal Investigator Damian Green, MD
Phase I

Research Study Description

This study tests the safety of a drug called SGN-CD352A, to find out what its side effects are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple myeloma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9736
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Hematologic Malignancies; Lymphoproliferative Disorders; Multiple Myeloma (MM); Immunoproliferative Disorders; Cardiovascular Diseases; Neoplasms, Plasma Cell; Paraproteinemias; Immune System Diseases; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials